Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Dermatological Burns, Scars & Ulcers: 2018 Drug Development Pipeline Review - ResearchAndMarkets.com

Research and Markets
Posted on: 24 Oct 18
The "Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the pipeline landscape for dermatological burns, scars and ulcers. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pressure ulcers, venous leg ulcers, burns and scars, and features dormant and discontinued products.
  • Pressure Ulcer: There are six products in development for this indication.
  • Venous Leg Ulcer: There are 14 products in development for this indication.
  • Burn: There are 32 products in development for this indication.
  • Scar: There are 20 products in development for this indication.

Molecular targets acted on by products in development for dermatological burns, scars and ulcers include integrins, interleukins and growth factors. Companies operating in this pipeline space include MediWound, Aegle Therapeutics and NovaLead Pharma.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

Companies Mentioned

  • Abzena Plc
  • AlgiPharma AS
  • Alliance Pharma Plc
  • Altacor Ltd
  • Amarantus Bioscience Holdings Inc
  • BirchBioMed Inc
  • CardioVascular BioTherapeutics Inc
  • CFM Pharma Holding BV
  • Cotinga Pharmaceuticals Inc
  • CytoTools AG
  • Daval International Ltd
  • Destiny Pharma Plc
  • Energenesis Biomedical Co Ltd
  • EyeGene Inc
  • Factor Therapeutics Ltd
  • FirstString Research Inc
  • GangaGen Inc
  • Izun Pharmaceuticals Corp
  • Kringle Pharma Inc
  • Madam Therapeutics BV
  • MallInckrodt Plc
  • MediWound Ltd
  • MimeTech Srl
  • Moerae Matrix Inc
  • NovaLead Pharma Pvt Ltd
  • Phagelux Inc
  • Pharmaxis Ltd
  • Promore Pharma AB
  • Resolys Bio Inc
  • RXi Pharmaceuticals Corp
  • Se-cure Pharmaceuticals Ltd
  • Synedgen Inc
  • Therapure Biopharma Inc
  • USV Pvt Ltd

For more information about this report visit https://www.researchandmarkets.com/research/953pzk/dermatological?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181024005308/en/

Business Wire
www.businesswire.com

Last updated on: 24/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.